Sign In
Buy LGND
$279.44
+17.27 (+6.59%)
At Close: Jun 23, 2026
Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering
04:00am, Tuesday, 23'rd Jun 2026
Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset
Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031
07:00am, Monday, 22'nd Jun 2026
Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offs
Ligand Pharmaceuticals Director Unloads 2,501 Shares — Should You Be Concerned?
07:00am, Sunday, 14'th Jun 2026
Kozarich sold 2,501 common shares. This transaction represented 5.65% of direct holdings.
Ligand Announces 2026 Investor Day in New York City
07:00am, Wednesday, 10'th Jun 2026
JUPITER, Fla., June 10, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor Day in New York City on Tuesday, December 8, 2026 at 1
A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million
08:28am, Sunday, 07'th Jun 2026
5,000 shares were sold for a total transaction value of ~$1.14 million on June 1, 2026, at a weighted average price around $227.06 per share. This sale represented 10.78% of Andrew Reardon's direct Co
Ligand to Participate in June Investor Conferences
04:01pm, Wednesday, 27'th May 2026
JUPITER, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor c
Saying Goodbye To The XOMA Royalty PFDs
08:00am, Monday, 25'th May 2026
Ligand Pharmaceuticals Incorporated will acquire XOMA Royalty Corporation for $39.00 per share in cash, totaling approximately $739 million. XOMA shareholders will receive a Contingent Value Right, or
Ligand Pharmaceuticals Q1 Earnings Call Highlights
04:13pm, Friday, 08'th May 2026
Ligand Pharmaceuticals NASDAQ: LGND reported first-quarter 2026 results that management said reflect the operating leverage of its royalty aggregation strategy, highlighted by growing royalties from k
Ligand Reports First Quarter 2026 Financial Results
07:00am, Thursday, 07'th May 2026
First quarter performance driven by strong year-over-year royalty revenue growth of 56% Reaffirms Previously Raised 2026 Full-Year Financial Guidance Reflecting Anticipated Partial-Year Contribution
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
08:01am, Wednesday, 06'th May 2026
NEW HOPE, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies
Ligand to Participate in May Investor Conferences
04:01pm, Tuesday, 05'th May 2026
JUPITER, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor c
BALA CYNWYD, Pa. , May 05, 2026 (GLOBE NEWSWIRE) -- Brodsky and Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky
Ligand Pharmaceuticals to Buy XOMA Royalty for $39/Share, Lifts 2026 Guidance and EPS Outlook
03:13pm, Wednesday, 29'th Apr 2026
Ligand Pharmaceuticals (NASDAQ: LGND) detailed plans to acquire XOMA Royalty Corporation in an investor call, outlining what executives described as a "highly complementary" transaction intended to ex
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of X
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation
03:06pm, Monday, 27'th Apr 2026
NEW YORK, April 27, 2026 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by XOMA Royalty Corporation (NASDAQ: XOMA) and its board of directors concerning the propo
